Lorus Virulizin pancreatic cancer data
This article was originally published in Pharmaceutical Approvals Monthly
Lorus Therapeutics believes its immunotherapy Virulizin could benefit a subgroup of pancreatic cancer patients with ECOG performance status of 0 or 1, the firm says Oct. 18. The Toronto biotech found, however, that its Phase III trial did not show statistical significance for median overall survival in chemo-naïve patients receiving Virulizin plus gemcitabine compared to placebo plus gemcitabine. "For the efficacy evaluable population, the study showed that the addition of Virulizin to gemcitabine resulted in a median [OS] of 6.8 months and a one-year survival rate of 27.2%, compared to 6.0 months and 16.8% for placebo plus gemcitabine," Lorus said. In ECOG PS 0/1 patients, "the result approached statistical significance with a p-value of 0.063"...
You may also be interested in...
Adding non-transfusion-dependent anemia patients to the Reblozyl label is a key strategy for the product, which BMS expects to reach $4bn in annual sales.
Biogen has warned that uptake for its newly approved Alzheimer’s therapy will be slow in the beginning and doctors confirm it will take time to figure which patients can and should be treated.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.